Ascendis Pharma (ASND)

• Market cap: $10.1B
• 1 day: -0.44%
• 5 days: 13.85%
• 1 month: 7.62%
• 3 months: 23.87%
• 6 months: 12.90%
• Year to date: 21.80%
• 1 year: 14.30%
• 5 years: 70.82%
• 10 years: 818.02%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Employees: 1,017

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

27% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 66

1.78% more ownership

Funds ownership: 104.07% [Q3] → 105.84% (+1.78%) [Q4]

3% less funds holding

Funds holding: 218 [Q3] → 211 (-7) [Q4]

6% less capital invested

Capital invested by funds: $9.33B [Q3] → $8.78B (-$549M) [Q4]

10% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 39

18% less funds holding in top 10

Funds holding in top 10: 17 [Q3] → 14 (-3) [Q4]

64% less call options, than puts

Call options by funds: $11.9M | Put options by funds: $32.7M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $196 17% upside
• Avg. target: $216 29% upside
• High target: $260 55% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

JP Morgan Jessica Fye 69% 1-year accuracy 27 / 39 met price target	19% upside $200	Overweight Maintained	18 Mar 2025
Cantor Fitzgerald Li Watsek 26% 1-year accuracy 11 / 43 met price target	19% upside $200	Overweight Maintained	25 Feb 2025
Evercore ISI Group Josh Schimmer 22% 1-year accuracy 12 / 55 met price target	55% upside $260	Outperform Maintained	18 Feb 2025
Goldman Sachs Paul Choi 50% 1-year accuracy 5 / 10 met price target	34% upside $225	Buy Maintained	13 Feb 2025
UBS Eliana Merle 25% 1-year accuracy 5 / 20 met price target	17% upside $196	Buy Initiated	7 Jan 2025